Cargando…

Características y evolución de los pacientes con amiloidosis sistémica y compromiso cardíaco

OBJECTIVE: To estimate the prevalence of cardiac amyloidosis in patients with systemic amyloidosis. Compare survival rates based on whether they show cardiac involvement. METHODS: A retrospective cohort study of patients with systemic amyloidosis from the Institutional Amyloidosis Registry of the Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Carretero, Marcelina, Aguirre, Ma A., Villanueva, Eugenia, Nucifora, Elsa, Posadas-Martínez, Ma Lourdes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Permanyer Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771037/
https://www.ncbi.nlm.nih.gov/pubmed/34187048
http://dx.doi.org/10.24875/ACM.21000011
_version_ 1784635508351041536
author Carretero, Marcelina
Aguirre, Ma A.
Villanueva, Eugenia
Nucifora, Elsa
Posadas-Martínez, Ma Lourdes
author_facet Carretero, Marcelina
Aguirre, Ma A.
Villanueva, Eugenia
Nucifora, Elsa
Posadas-Martínez, Ma Lourdes
author_sort Carretero, Marcelina
collection PubMed
description OBJECTIVE: To estimate the prevalence of cardiac amyloidosis in patients with systemic amyloidosis. Compare survival rates based on whether they show cardiac involvement. METHODS: A retrospective cohort study of patients with systemic amyloidosis from the Institutional Amyloidosis Registry of the Hospital Italian of Buenos Aires from 2010 to 2019. Heart involvement is considered to be the presence of symptoms and/or images consistent with amyloidosis, and there is no other reason to explain it. All deaths due to causes were evaluated. The survival rate was estimated by Kaplan-Meier. Cox regression model was used to evaluate factors related to mortality. Heart transplantation was evaluated in a competitive risk regression model. RESULTS: The prevalence of heart involvement is 63%. For the group with heart damage, the death rate was 14/1,000 person-months, and for patients without damage, the death rate was 5/1,000 person-months. The 5-year overall survival rate for patients with heart involvement was 44%, while that for patients without damage was 67% (p = 0.02). The original HR for heart involvement was 2.09 (p = 0.02). Age showed that HRa was 1.06 (p <0.01). The sub-HR estimated by the competitive risk regression model are 1.86 (95% CI 0.99-3.49) p = 0.05. CONCLUSION: Cardiac involvement is an important prognostic factor in patients with amyloidosis.
format Online
Article
Text
id pubmed-8771037
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Permanyer Publications
record_format MEDLINE/PubMed
spelling pubmed-87710372022-01-24 Características y evolución de los pacientes con amiloidosis sistémica y compromiso cardíaco Carretero, Marcelina Aguirre, Ma A. Villanueva, Eugenia Nucifora, Elsa Posadas-Martínez, Ma Lourdes Arch Cardiol Mex Artículo De Investigación OBJECTIVE: To estimate the prevalence of cardiac amyloidosis in patients with systemic amyloidosis. Compare survival rates based on whether they show cardiac involvement. METHODS: A retrospective cohort study of patients with systemic amyloidosis from the Institutional Amyloidosis Registry of the Hospital Italian of Buenos Aires from 2010 to 2019. Heart involvement is considered to be the presence of symptoms and/or images consistent with amyloidosis, and there is no other reason to explain it. All deaths due to causes were evaluated. The survival rate was estimated by Kaplan-Meier. Cox regression model was used to evaluate factors related to mortality. Heart transplantation was evaluated in a competitive risk regression model. RESULTS: The prevalence of heart involvement is 63%. For the group with heart damage, the death rate was 14/1,000 person-months, and for patients without damage, the death rate was 5/1,000 person-months. The 5-year overall survival rate for patients with heart involvement was 44%, while that for patients without damage was 67% (p = 0.02). The original HR for heart involvement was 2.09 (p = 0.02). Age showed that HRa was 1.06 (p <0.01). The sub-HR estimated by the competitive risk regression model are 1.86 (95% CI 0.99-3.49) p = 0.05. CONCLUSION: Cardiac involvement is an important prognostic factor in patients with amyloidosis. Permanyer Publications 2022 2021-06-28 /pmc/articles/PMC8771037/ /pubmed/34187048 http://dx.doi.org/10.24875/ACM.21000011 Text en Copyright: © 2022 Permanyer https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Artículo De Investigación
Carretero, Marcelina
Aguirre, Ma A.
Villanueva, Eugenia
Nucifora, Elsa
Posadas-Martínez, Ma Lourdes
Características y evolución de los pacientes con amiloidosis sistémica y compromiso cardíaco
title Características y evolución de los pacientes con amiloidosis sistémica y compromiso cardíaco
title_full Características y evolución de los pacientes con amiloidosis sistémica y compromiso cardíaco
title_fullStr Características y evolución de los pacientes con amiloidosis sistémica y compromiso cardíaco
title_full_unstemmed Características y evolución de los pacientes con amiloidosis sistémica y compromiso cardíaco
title_short Características y evolución de los pacientes con amiloidosis sistémica y compromiso cardíaco
title_sort características y evolución de los pacientes con amiloidosis sistémica y compromiso cardíaco
topic Artículo De Investigación
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771037/
https://www.ncbi.nlm.nih.gov/pubmed/34187048
http://dx.doi.org/10.24875/ACM.21000011
work_keys_str_mv AT carreteromarcelina caracteristicasyevoluciondelospacientesconamiloidosissistemicaycompromisocardiaco
AT aguirremaa caracteristicasyevoluciondelospacientesconamiloidosissistemicaycompromisocardiaco
AT villanuevaeugenia caracteristicasyevoluciondelospacientesconamiloidosissistemicaycompromisocardiaco
AT nuciforaelsa caracteristicasyevoluciondelospacientesconamiloidosissistemicaycompromisocardiaco
AT posadasmartinezmalourdes caracteristicasyevoluciondelospacientesconamiloidosissistemicaycompromisocardiaco